Sign in
CompletedPhase 4

Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

Key facts

Who runs it
Dow University of Health Sciences
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
120 people enrolled
Started
6 Apr 2025
Ended
5 Jan 2026
Type of study
Interventional, 3 groups
Treatments tested
  • ruxolitinib cream
Record updated
26 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • adult aged 18 to 65 years male or female patients non-segmental vitiligo vitiligo involving less then 10% body surface area willingness to provide written informed consent

Who cannot take part

  • pregnant or lactating females known hypersentivity to ruxolitinib, tacrolimus or topical corticosteriods current use of systemic immunosuppressive therapy use of biologic therapy or phototherapy within the previous 12 weeks

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

this randomized controlled trial aims to compare the effectiveness and safety of ruxolitinib monotherapy versus its combination with topical tacrolimus or topical corticosteroids in patients with non-segmental vitiligo involving less than 10% body surface area. A total of 120 adult patients will be randomized into three treatment groups and followed for 24 weeks. Treatment response will be evaluated using validated scoring systems including the Vitiligo Area Severity Index (VASI), Vitiligo European Task Force (VETF) staging, and Physician Global Assessment. The findings may help optimize topical treatment strategies for vitiligo.

The 3 groups in the trial

  • group aOther group

    ruxolitinib monotherapy

    Treatment: ruxolitinib cream

  • group bOther group

    ruxolitinib with tacrolimus

    Treatment: ruxolitinib cream

  • group cOther group

    ruxolitinib with corticosteriods

    Treatment: ruxolitinib cream

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 January 2026